IOL Chemicals and Pharmaceuticals net profit rises 43.5% to Rs.107.2 crore in 9M FY24

▴ IOLCP
The company is the World’s largest producer of Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR-approved R&D which is fully equipped to validate existing processes.

     Total income for 9M FY24 stood at Rs.1,651 crore against Rs.1,647 crore YoY

  • EBITDA for 9M FY24 at Rs.204.0 crore up by 38.4% YoY
  • Net profit for 9M FY24 at Rs.107.2 crore up by 43.5% YoY
  • Received CEP Certificate for Losartan Potassium issued by EDQM which will enable higher export to European market
  • The Board declared an Interim Dividend of Rs.5/- Share

 

08th February, 2024, New Delhi:

IOL Chemicals and Pharmaceuticals Ltd, a leading manufacturer of pharmaceutical APIs and speciality chemicals, announced its financial results for the third quarter and nine months ended December 31, 2023.

 

Consolidated Q3 & 9M FY24 Financial Highlights                                          

                                                                                                                                                  (Rs. in Crore)

Particulars

Q3 FY24

Q3 FY23

% YoY

9M FY24

9M FY23

% YoY

Total Income

528.8

530.1

-0.2%

1651.4

1,646.8

0.3%

EBITDA

52.9

49.7

6.4%

204.0

147.6

38.2%

EBITDA Margin (%)

10.0%

9.4%

60 bps

12.3%

8.9%

340 bps

PAT

23.2

24.2

-4.1%

107.2

74.7

43.5%

PAT Margin (%)

4.4%

4.6%

-20 bps

6.5%

4.5%

200 bps

 

Commenting on the performance, Mr Vikas Gupta, Joint Managing Director said, “Despite sectoral headwinds, the Company has shown resilience in its financial performance during nine months period. The company’s EBITDA margin has improved led by declining input cost. We recently received CEP certificate approval for Losartan Potassium by EDQM providing us an opportunity to further expand our exports into the regulated markets. We are continuously focusing on improving operational efficiencies further through backward integration.”


 

 

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Established in 1986 and listed on the National Stock Exchange of India Ltd (Code: IOLCP) and BSE Ltd (Code: 524164), IOL Chemicals and Pharma is one of the leading pharmaceutical (APIs) Companies and a significant player in the specialty chemicals space with world-class facilities. IOLCP has a wide presence across major therapeutic categories like Pain Management, anti-convulsants, anti-diabetes, anti-cholesterol and anti-platelets.

 

The Company’s product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole, Paracetamol and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

 

The company is the World’s largest producer of Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR-approved R&D which is fully equipped to validate existing processes.

 

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with Zero Liquid Discharge (ZLD) system along with a 17 MW captive Co-Generation plant for self-reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

 

IOLCP's overseas customers are spread out across several countries including the UK, Belgium, Hungry, Spain, Germany, Italy, Netherlands, Switzerland, Poland, Ireland, USA, Peru, Brazil, Argentina, Colombia, Indonesia, South Korea, Thailand, Bangladesh, Turkey, U.A.E., China, Hong Kong, Egypt etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Tags : #

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Sanjeevani Healthcare & Wellness Expo 2024: A Dynamic Platform for Global Healthcare CollaborationDecember 23, 2024
Ranitidine: Saviour or Suspect? The Truth Behind the Stomach Acid RemedyDecember 23, 2024
From One-Size-Fits-All to Precision Medicine: The New Hope for Rare Bone Cancer PatientsDecember 23, 2024
World Meditation Day: India’s Gift of Peace to a Chaotic WorldDecember 23, 2024
Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and TreatmentDecember 23, 2024
Black Angels remind us of centuries of injustices plaguing the TB responseDecember 20, 2024
Healthcare Startups to Watch Out for in 2025December 20, 2024
Biobank Blueprint: Redefining Diabetes Diagnosis and Treatment in IndiaDecember 20, 2024
The Future of Malaria Prevention: Can This Vaccine Eliminate the Disease?December 20, 2024
Why the World Trusts Indian Pharmaceuticals for Life-Saving SolutionsDecember 20, 2024
International Tsunami Conference Concludes at AmritapuriDecember 20, 2024
Prestige Marks 75 Years of Revolutionizing Home Cooking with Iconic Innovative ProductsDecember 20, 2024
Revolutionizing Education: Online Learning Platforms Transforming Study Materials for Board and Competitive ExamsDecember 19, 2024
Why Your Blood Pressure Reading Might Be a Lie and How to Fix ItDecember 19, 2024
Vaccines, Cards, and Digital Records: How India is Fighting Healthcare InequalityDecember 19, 2024
Bridging Borders: Sri Lanka’s President Explores India’s Healthcare and HeritageDecember 19, 2024
Jeevan Jyoti Project Brings Eye Care to Alwar's Rural CommunitiesDecember 19, 2024
Crompton Launches New Range of Decorative Wall Lights Providing a Perfect Blend of Uniqueness & AestheticsDecember 19, 2024
Can One Injection End Decades of HIV Inequality?December 19, 2024
Multi-Organ Marvel: How a 12-Hour Surgery Gave a Businessman New LifeDecember 19, 2024